An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-07-01
Schriftenreihe:	EBioMedicine
Schlagworte:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!